Advances on drug management in patients with inflammatory bowel disease

doi:10.3969/j.issn.1674-490X.2022.02.009

Abstract

Abstract: In recent years, the incidence of inflammatory bowel diseases(IBD)has been increasing in China, and it is a common digestive system disease mainly manifested as long-term and persistent repeated inflammation. This paper induced, summarized and analyzed relevant literatures on drug management of IBD patients at home and abroad in recent years, and expounded whether it could improve patients' drug management ability, improve their cognition of disease and improve their quality of life, so as to provide reference for hospitals or communities to implement drug management of IBD.

Key words: inflammatory bowel diseases, drug management, medication compliance, ulcerative colitis, Crohn's disease

CLC Number:

R322.4

LUO Fameng, LIU Rong, ZHANG Haiyan. Advances on drug management in patients with inflammatory bowel disease[J]. Journal of Hebei Medical College for Continuing Education, 2022, 39(2): 66-71.

References

[1] GUAN Q D. A comprehensive review and update on the pathogenesis of inflammatory bowel disease[J]. J Immunol Res, 2019, 2019: 7247238. DOI: 10.1155/2019/7247238.
[2] NAKASE H, UCHINO M, SHINZAKI S, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020[J]. J Gastroenterol, 2021, 56(6): 489-526. DOI: 10.1007/s00535-021-01784-1.
[3] 柳慧,张玉洁,吴开春.炎症性肠病临床研究现状及进展[J].临床内科杂志, 2021, 38(2): 90-93. DOI: 10.3969/j.issn.1001-9057.2021.02.006.
[4] 李学锋,彭霞,周明欢.我国炎症性肠病流行病学研究进展[J].现代消化及介入诊疗, 2020, 25(9): 1265-1267. DOI: 10.3969/j.issn.1672-2159.2020.09.032.
[5] SELVARATNAM S, GULLINO S, SHIM L, et al. Epidemiology of inflammatory bowel disease in South America: a systematic review[J]. World J Gastroenterol, 2019, 25(47): 6866-6875. DOI: 10.3748/wjg.v25.i47.6866.
[6] WABICH J, BELLAGUARDA E, JOYCE C, et al. Disordered eating, body dissatisfaction, and psychological distress in patients with inflammatory bowel disease(IBD)[J]. J Clin Psychol Med Settings, 2020, 27(2): 310-317. DOI: 10.1007/s10880-020-09710-y.
[7] 关玉霞,尤丽丽,何叶,等.炎症性肠病病人自我效能、疾病活动度与生存质量的相关性[J]. 护理研究, 2020, 34(11): 1921-1925. DOI: 10.12102/j.issn.1009-6493.2020.11.010.
[8] 胡兴.炎症性肠病患者自我管理能力的现状及干预研究[D].合肥:安徽医科大学, 2019:5-6.
[9] STEINBERG J M, CHARABATY A. The management approach to the adolescent IBD patient: health maintenance and medication considerations[J]. Curr Gastroenterol Rep, 2020, 22(1): 5. DOI: 10.1007/s11894-019-0739-9.
[10] 吴全峰,赵立波,王晓玲,等.炎症性肠病的治疗药物研究进展[J].中国药师, 2020, 23(10): 2011-2019. DOI: 10.3969/j.issn.1008-049X.2020.10.033.
[11] 谭秋丰.托拉塞米联合甲基泼尼松龙治疗肾病综合征并发急性肾衰竭的临床疗效[J].临床合理用药杂志, 2021, 14(18): 73-75. DOI: 10.15887/j.cnki.13-1389/r.2021.18.026.
[12] 张宁,张林丽,贾安.炎症性肠病治疗药物研究进展[J].药学与临床研究, 2020, 28(4): 275-278, 282. DOI: 10.13664/j.cnki.pcr.2020.04.009.
[13] 刘元德,弓三东.重度克罗恩病的治疗进展[J].海南医学, 2019, 30(20): 2691-2695. DOI: 10.3969/j.issn.1003-6350.2019.20.031.
[14] 吴开春,梁洁,冉志华, 等.炎症性肠病诊断与治疗的共识意见(2018年·北京)[J]. 中国实用内科杂志, 2018, 38(9): 796-813. DOI: 10.19538/j.nk2018090106.
[15] LIMA C C G, QUEIROZ N S F, SOBRADO C W, et al. Critical analysis of anti-tnf use in the era of new biological agents in inflammatory bowel disease[J]. Arq Gastroenterol, 2020, 57(3): 323-332. DOI: 10.1590/s0004-2803.202000000-59.
[16] 郑雅丹,李岭,庞智.炎症性肠病生物治疗的最新研究进展[J].胃肠病学和肝病学杂志, 2020, 29(2): 212-218. DOI: 10.3969/j.issn.1006-5709.2020.02.019.
[17] RESNICK B. Research review: self-administration of medication in hospital: patients' perspectives[J]. Geriatr Nurs, 2004, 25(5): 309-310. DOI: 10.1016/j.gerinurse.2004.08.013.
[18] American Pharmacists Association, National Association of Chain Drug Stores Foundation. Medication therapy management in pharmacy practice: core elements of an MTM service model(version 2.0)[J]. J Am Pharm Assoc(2003), 2008, 48(3): 341-353. DOI: 10.1331/JAPhA.2008.08514.
[19] BALAII H, OLYANASAB NARAB S, KHANABADI B, et al. Determining the degree of adherence to treatment in inflammatory bowel disease patients[J]. Gastroenterol Hepatol Bed Bench, 2018, 11(Suppl 1): S39-S44.
[20] 王琼芳,曹冬霞,陈晓容.多学科团队协作护理模式在炎症性肠病患者中的应用进展[J].当代护士(上旬刊), 2021, 28(1): 13-15. DOI: 10.19791/j.cnki.1006-6411.2021.01.004.
[21] 刘晓琳.云南省炎症性肠病患者药物依从性及疾病知识现状的调查[D].昆明:昆明医科大学, 2017:21-22.
[22] LIM J K, LEE Y J, PARK J H. Medication-related knowledge and medication adherence in pediatric and adolescent patients with inflammatory bowel disease[J]. J Korean Med Sci, 2020, 35(14): e92. DOI: 10.3346/jkms.2020.35.e92.
[23] 曹丹,朱秀琴.炎症性肠病患者自我管理的研究进展[J].世界华人消化杂志, 2019, 27(12): 773-777.
[24] 罗丹,林征,卞秋桂,等.炎症性肠病患者感知病耻感现状及其对生活质量、服药依从性和心理状态的影响[J].中华护理杂志, 2018, 53(9): 1078-1083. DOI: 10.3761/j.issn.0254-1769.2018.09.012.
[25] LAI W W, CAI S H. Comment on “prevalence of anxiety and depression in patients with inflammatory bowel disease”[J]. Can J Gastroenterol Hepatol, 2018, 2018: 6747630. DOI: 10.1155/2018/6747630.
[26] 罗丹,林征,卞秋桂,等.炎症性肠病患者自我管理体验质性研究的系统评价[J].中华护理杂志, 2018, 53(1): 41-47. DOI: 10.3761/j.issn.0254-1769.2018.01.008.
[27] YAMABE K, LIEBERT R, FLORES N, et al. Health-related quality of life outcomes and economic burden of inflammatory bowel disease in Japan[J]. Clinicoecon Outcomes Res, 2019, 11: 221-232. DOI: 10.2147/CEOR.S179892.
[28] TOMAR S K, KEDIA S, SINGH N, et al. Higher education, professional occupation, and upper socioeconomic status are associated with lower adherence to medications in patients with inflammatory bowel disease[J]. JGH Open, 2019, 3(4): 302-309. DOI: 10.1002/jgh3.12160.
[29] KAMP K J, WEST P, HOLMSTROM A, et al. Systematic review of social support on psychological symptoms and self-management behaviors among adults with inflammatory bowel disease[J]. J Nurs Scholarsh, 2019, 51(4): 380-389. DOI: 10.1111/jnu.12487.
[30] 李佳昕,任宏飞,王瑞,等.炎症性肠病患者自我管理现状及影响因素研究[J].四川医学, 2021, 42(4): 358-364. DOI: 10.16252/j.cnki.issn1004-0501-2021.04.008.
[31] 朱迎,林征,丁霞芬,等.炎症性肠病患者疾病知识与需求调查分析[J].中华护理杂志, 2014, 49(1): 66-70. DOI: 10.3761/j.issn.0254-1769.2014.01.017.
[32] 崔静文.炎症性肠病患者药物自我管理水平测评量表的编制与应用[D].镇江:江苏大学, 2020:1-2.
[33] 周美景,罗丹,林征,等.炎症性肠病患者自我管理行为的影响因素分析[J].中华护理杂志, 2021, 56(4): 550-555. DOI: 10.3761/j.issn.0254-1769.2021.04.012.
[34] 朱丹玲.炎症性肠病患者自我管理体验的质性研究[D].杭州:浙江中医药大学, 2019:25-50.
[35] 徒文静,徐桂华.炎症性肠病患者成人初显期管理的研究进展及启示[J].中国全科医学, 2021, 24(15): 1861-1866. DOI: 10.12114/j.issn.1007-9572.2021.00.426.